Genomically Guided Radiation Therapy for Breast Cancer (Triple Negative Breast Cancer (TNBC))
Phase-Based Progress Estimates
Effectiveness
Safety
Moffitt Cancer Center, Tampa, FL
Breast Cancer (Triple Negative Breast Cancer (TNBC))+2 More
Genomically Guided Radiation Therapy - RadiationEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Eligible Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Treatment Effectiveness
Effectiveness Progress
Other trials for Breast Cancer (Triple Negative Breast Cancer (TNBC))
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Up to 5 Years
At 3 Years
Local Control
Up to 5 Years
Distant Control
Overall Survival (OS)
Quality of Life following Genomically Guided Dose Personalization
Up to 5 years
Progression Free Survival (PFS)
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Breast Cancer (Triple Negative Breast Cancer (TNBC))
Trial Design
2 Treatment Groups
Radiosensitivity Index not optimized
1 of 2
Radiosensitivity Index optimized
1 of 2
Active Control
Experimental Treatment
86 Total Participants · 2 Treatment Groups
Primary Treatment: Genomically Guided Radiation Therapy · No Placebo Group · Phase 2
Radiosensitivity Index optimized
Radiation
Experimental Group · 1 Intervention: Genomically Guided Radiation Therapy · Intervention Types: RadiationRadiosensitivity Index not optimized
Radiation
ActiveComparator Group · 1 Intervention: Genomically Guided Radiation Therapy · Intervention Types: RadiationTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
Closest Location: Moffitt Cancer Center · Tampa, FL
2009First Recorded Clinical Trial
15 TrialsResearching Breast Cancer (Triple Negative Breast Cancer (TNBC))
222 CompletedClinical Trials
Who is running the clinical trial?
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
486 Previous Clinical Trials
123,316 Total Patients Enrolled
3 Trials studying Breast Cancer (Triple Negative Breast Cancer (TNBC))
148 Patients Enrolled for Breast Cancer (Triple Negative Breast Cancer (TNBC))
Kamran Ahmed, MDPrincipal InvestigatorMoffitt Cancer Center
2 Previous Clinical Trials
53 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have TN breast cancer.
You have a life expectancy of at least 16 weeks.
You are recovering from surgery and are cleared by your surgeon.
You are of childbearing potential and are sexually active
You must be able to give informed consent before study enrollment.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments